The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
A review of the receptor-binding and pharmacokinetic properties of dopamine agonists
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rascol, O., Brooks, D. J., Korczyn, A. D., De Deyn, P. P., Clarke, C. E., & Lang, A. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422004 · Cited by 1,539
Samii, A., Nutt, J. G., & Ransom, B. R. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16305-8 · Cited by 1,265
Restless Legs Syndrome Prevalence and Impact: REST General Population Study
Allen, R. P., Walters, A. S., Montplaisir, J., Hening, W., Myers, A., Bell, T. J., & Ferini-Strambi, L. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.11.1286 · Cited by 1,182
Depression and Parkinson's disease: a review
(1992) · American Journal of Psychiatry · doi:10.1176/ajp.149.4.443 · Cited by 1,111
An algorithm (decision tree) for the management of Parkinson’s disease (2001): Treatment Guidelines
Olanow, C. W., Watts, R. L., & Koller, W. C. (2001) · Neurology · doi:10.1212/wnl.56.suppl_5.s1 · Cited by 715
Ingelman-Sundberg, M. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.02.007 · Cited by 676
Range of neuropsychiatric disturbances in patients with Parkinson's disease
Aarsland, D., Larsen, J. P., Lim, N. G., Janvin, C., Karlsen, K., Tandberg, E., & Cummings, J. L. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.67.4.492 · Cited by 581
Millan, M. J., Maiofiss, L., Cussac, D., Audinot, V., Boutin, J.-A., & Newman-Tancredi, A. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.039867 · Cited by 484
Newer antidepressants and the cytochrome P450 system
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.3.311 · Cited by 482
Goetz, C. G., Poewe, W., Rascol, O., & Sampaio, C. (2005) · Movement Disorders · doi:10.1002/mds.20464 · Cited by 376
Deleu, D., Northway, M. G., & Hanssens, Y. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241040-00003 · Cited by 349
Rinne, U., Bracco, F., Chouza, C., Dupont, E., Gershanik, O., Masso, J. M., Montastruc, J., & Marsden, C. (1998) · Drugs · doi:10.2165/00003495-199855001-00004 · Cited by 324
Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease
Van Camp, G., Flamez, A., Cosyns, B., Weytjens, C., Muyldermans, L., Van Zandijcke, M., De Sutter, J., Santens, P., Decoodt, P., Moerman, C., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15945-x · Cited by 321
Handbook of Parkinson's Disease
(2013) · CRC Press eBooks · doi:10.1201/b14361 · Cited by 272
Effect of St John's wort on imatinib mesylate pharmacokinetics
FRYE, R., FITZGERALD, S., LAGATTUTA, T., HRUSKA, M., & EGORIN, M. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.06.007 · Cited by 258
Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors
Mierau, J., Schneider, F. J., Ensinger, H. A., Chio, C. L., Lajiness, M. E., & Huff, R. M. (1995) · European Journal of Pharmacology: Molecular Pharmacology · doi:10.1016/0922-4106(95)90013-6 · Cited by 257
Severe multivalvular heart disease: A new complication of the ergot derivative dopamine agonists
Horvath, J., Fross, R. D., Kleiner‐Fisman, G., Lerch, R., Stalder, H., Liaudat, S., Raskoff, W. J., Flachsbart, K. D., Rakowski, H., Pache, J., et al. (2004) · Movement Disorders · doi:10.1002/mds.20201 · Cited by 243
CYP2D6 polymorphism, pesticide exposure, and Parkinson's disease
Elbaz, A., Levecque, C., Clavel, J., Vidal, J., Richard, F., Amouyel, P., Alpérovitch, A., Chartier‐Harlin, M., & Tzourio, C. (2004) · Annals of Neurology · doi:10.1002/ana.20051 · Cited by 213
Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study
Oertel, W. H., Wolters, E., Sampaio, C., Gimenez‐Roldan, S., Bergamasco, B., Dujardin, M., Grosset, D. G., Arnold, G., Leenders, K. L., Hundemer, H., et al. (2006) · Movement Disorders · doi:10.1002/mds.20724 · Cited by 210
The mesolimbic dopamine system as a target for rapid antidepressant action
Willner, P. (1997) · International Clinical Psychopharmacology · doi:10.1097/00004850-199707003-00002 · Cited by 208
Olanow, C. W., Fahn, S., Muenter, M., Klawans, H., Hurtig, H., Stern, M., Shoulson, I., Kurlan, R., Grimes, J. D., Jankovic, J., et al. (1994) · Movement Disorders · doi:10.1002/mds.870090107 · Cited by 204
Clinical Pharmacokinetics of Ropinirole
Kaye, C. M., & Nicholls, B. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200039040-00001 · Cited by 175
Pogarell, O. (2002) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.72.6.713 · Cited by 165
Wang, L., Zhou, G., Zhu, B. Y., Wu, J., Wang, J., El‐Aty, A. M. A., Li, T., Liu, J., Tian-lun, Y., Wang, D., et al. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.09.014 · Cited by 145
TANNERGREN, C. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.12.012 · Cited by 138
Möller, J. C., Oertel, W., Köster, J., Pezzoli, G., & Provinciali, L. (2005) · Movement Disorders · doi:10.1002/mds.20397 · Cited by 135
Pergolide use in Parkinson disease is associated with cardiac valve regurgitation
Baseman, D., O’Suilleabhain, P. E., Reimold, S. C., Laskar, S. R., Baseman, J. G., & Dewey, R. B. (2004) · Neurology · doi:10.1212/01.wnl.0000129842.49926.07 · Cited by 119
Steady‐State Pharmacokinetic Properties of Pramipexole in Healthy Volunteers
Wright, C. E., Sisson, T. L., Ichhpurani, A. K., & Peters, G. R. (1997) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1997.tb04330.x · Cited by 117
Heart valvular disease in patients with Parkinson’s disease treated with high-dose pergolide
Camp, G. V., Flamez, A., Cosyns, B., Goldstein, J. W., Perdaens, C., & Schoors, D. (2003) · Neurology · doi:10.1212/01.wnl.0000083985.00343.f2 · Cited by 115
McCann, S. J., Pond, S. M., James, K. M., & Couteur, D. G. L. (1997) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(97)00179-2 · Cited by 115
Agonism at 5-HT2B receptors is not a class effect of the ergolines
Jähnichen, S., HOROWSKI, R., & Pertz, H. H. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.03.010 · Cited by 106
Fibrotic Valvular Heart Disease Subsequent to Bromocriptine Treatment
Serratrice, J., DISDIER, P., Habib, G., Viallet, F., & Weiller, P. (2002) · Cardiology in Review · doi:10.1097/00045415-200211000-00005 · Cited by 106
Depression in Parkinson's disease
Allain, H. (2000) · BMJ · doi:10.1136/bmj.320.7245.1287 · Cited by 104
Wenk, M., Todesco, L., & Krähenbühl, S. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2003.02049.x · Cited by 82
Joyce, J. N., Ryoo, H., Beach, T., Caviness, J. N., Stacy, M. A., Gurevich, E. V., Reiser, M., & Adler, C. H. (2002) · Brain Research · doi:10.1016/s0006-8993(02)03396-6 · Cited by 68
Deng, Y., Newman, B. M., Dunne, M. P., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20143 · Cited by 62
Association between the oxidative polymorphism and early onset of Parkinson's disease*
Agúndez, J. A. G., Jiménez‐Jiménez, F. J., Luengo, A., Bernal, M. L., Molina, J. A., Ayuso, L. L., Vázquez, A., Parra, J., Duarte, J., Coria, F., et al. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90154-x · Cited by 62
Inzelberg, R., Schechtman, E., & Nisipeanu, P. (2003) · Drugs & Aging · doi:10.2165/00002512-200320110-00006 · Cited by 51
Fibrosis Associated With Dopamine Agonist Therapy in Parkinson's Disease
Müller, T. H., & Fritze, J. (2003) · Clinical Neuropharmacology · doi:10.1097/00002826-200305000-00001 · Cited by 49
Andreotti, A. C., Pianezzola, E., Persiani, S., Pacciarini, M. A., Benedetti, M. S., & Pontiroli, A. E. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.80.3.841 · Cited by 49
Dhawan, V., Medcalf, P., Stegie, F., Jackson, G. S., Basu, S., Luce, P. J., Odin, P., & Chaudhuri, К. R. (2005) · Journal of Neural Transmission · doi:10.1007/s00702-005-0289-1 · Cited by 46
Csako, G., McGriff, N. J., Rotman-Pikielny, P., Sarlis, N. J., & Pucino, F. (2001) · Annals of Pharmacotherapy · doi:10.1345/aph.1a031 · Cited by 40
Pharmacokinetic evaluation of erythromycin and caffeine administered with bromocriptine
Nelson, M. V., Berchou, R. C., Kareti, D., & LeWitt, P. A. (1990) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1990.95 · Cited by 37
Plasma tacrine concentrations are significantly increased by concomitant hormone replacement therapy
LAINE, K., Palovaara, S., TAPANAINEN, P., & MANNINEN, P. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1053/cp.1999.v66.103404001 · Cited by 32
Choosing Dopamine Agonists in Parkinson's Disease
Tan, E., & Jankovic, J. J. (2001) · Clinical Neuropharmacology · doi:10.1097/00002826-200109000-00001 · Cited by 30
Nakatsuka, A., Nagai, M., Yabe, H., et al. (2006) · Journal of Pharmacological Sciences · doi:10.1254/jphs.fp0050711 · Cited by 27
Townsend, M., & MacIver, D. H. (2004) · Heart · doi:10.1136/hrt.2004.036236 · Cited by 26
D1 dopamine receptor activity of anti-Parkinsonian drugs
Fici, G. J., Wu, H., Voigtlander, P. F. V., & Sethy, V. H. (1997) · Life Sciences · doi:10.1016/s0024-3205(97)00126-4 · Cited by 24
Cabergoline plasma concentration is increased during concomitant treatment with itraconazole
Christensen, J., Dupont, E., & Østergaard, K. (2002) · Movement Disorders · doi:10.1002/mds.10250 · Cited by 10
Cited by
Physiological basis of transcranial direct current stimulation
Stagg, C. J., & Nitsche, M. A. (2011) · The Neuroscientist · doi:10.1177/1073858410386614 · Cited by 1,719
The determination and interpretation of the therapeutic index in drug development
Muller, P. Y., & Milton, M. N. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3801 · Cited by 563
Earley, C. J., Connor, J., Garcia-Borreguero, D., Jenner, P., Winkelman, J., Zee, P. C., & Allen, R. (2014) · Sleep Medicine · doi:10.1016/j.sleep.2014.05.009 · Cited by 336
Kern, A., Albarran-Zeckler, R., Walsh, H. E., & Smith, R. G. (2012) · Neuron · doi:10.1016/j.neuron.2011.10.038 · Cited by 315
HaloTag Technology: A Versatile Platform for Biomedical Applications
England, C. G., Luo, H., & Cai, W. (2015) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00191 · Cited by 311
Metadata
- Authors
- Kvernmo, T., Härtter, S., & Burger, E.
- Venue
- Clinical Therapeutics
- Publisher
- Elsevier BV
- Published
- 2006-08
- Volume
- 28
- Issue
- 8
- Pages
- 1065-1078
- ISSN
- 0149-2918 (ISSN-L)
- OpenAlex
- W2090055848
- Cited by
- 277
- References
- 49
- FWCI
- 7.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.